Search

Displaying results 1321 - 1330 of 4539 in total
  1. Drug

    Zuclopenthixol

    go.drugbank.com/drugs/DB01624
    ApprovedInvestigational

    It is known that zuclopenthixol is metabolized by Cytochrome P450 2D6. Zuclopenthixol was approved for use in Canada in 2011, but is not approved for use in the United States. … These are organic polycyclic compounds containing a thioxanthene moiety, which is an aromatic tricycle derived from xanthene by replacing the oxygen atom with a sulfur atom.

  2. Drug

    scAAV9.U7.ACCA

    go.drugbank.com/drugs/DB18582
    Investigational

    Developed by Nationwide Children’s Hospital, it is being investigated for the treatment of Duchenne muscular dystrophy. … scAAV9.U7.ACCA is a non-replicating recombinant adeno-associated virus vector containing 4 antisense sequences designed to target exon 2 in the human DMD gene under the control of U7 small nuclear non-coding

    Synonyms: scAAV9.U7.ACCA, non-replicating recombinant adeno-associated virus vector containing 4 antisense sequences designed to target exon 2 in the human DMD gene under the control of U7 small nuclear non-coding RNA
  3. Drug

    Dydrogesterone

    go.drugbank.com/drugs/DB00378
    ApprovedInvestigationalWithdrawn

    A synthetic progestational hormone with no androgenic or estrogenic properties. Unlike many other progestational compounds, dydrogesterone produces no increase in temperature and does not inhibit ovulation.

  4. Drug

    Pegfilgrastim

    go.drugbank.com/drugs/DB00019
    ApprovedInvestigational

    [A187607] First developed by Amgen, pegfilgrastim was initially approved by the FDA in 2002 and marketed as Neulasta. It is typically administered via a subcutaneous injection. … [A187601] The drug is approved for use to decrease the incidence of infection, as manifested by febrile neutropenia, in susceptible patients with with non-myeloid cancer receiving myelosuppressive anti-cancer

  5. Drug

    Gallamine triethiodide

    go.drugbank.com/drugs/DB00483
    ApprovedWithdrawn

    It should be used cautiously in patients at risk from increased heart rate but may be preferred for patients with bradycardia. (From AMA Drug Evaluations Annual, 1992, p198) … The actions of gallamine triethiodide are similar to those of tubocurarine, but this agent blocks the cardiac vagus and may cause sinus tachycardia and, occasionally, hypertension and increased cardiac

  6. Drug

    Rotigotine

    go.drugbank.com/drugs/DB05271
    ApprovedInvestigational

    It was approved by the European Medicines Agency in 2006 and by the FDA in 2007. … Rotigotine was developed by Aderis Pharmaceuticals. In 1998 Aderis licensed worldwide development and commercialization rights to Schwarz Pharma of Germany.

  7. Drug

    Estazolam

    go.drugbank.com/drugs/DB01215
    ApprovedIllicitInvestigational

    A benzodiazepine with anticonvulsant, hypnotic, and muscle relaxant properties. It has been shown in some cases to be more potent than diazepam or nitrazepam.

  8. Drug

    Triflusal

    go.drugbank.com/drugs/DB08814
    ApprovedWithdrawn

    Triflusal is a 2-acetoxy-4-trifluoromethylbenzoic acid and it is an aspirin chemically-related molecule but not a derivative. … [A31675] It is very important as a secondary prevention of ischemic stroke by offering a lower risk of bleeding.[A31676] It was developed by J.

  9. Drug

    MK-3577

    go.drugbank.com/drugs/DB14957
    Investigational

    MK-3577 is under investigation in clinical trial NCT00868790 (A Study of the Safety and Efficacy of MK-3577 in Participants With Type 2 Diabetes Mellitus (MK-3577-009)).

  10. Drug

    Faropenem medoxomil

    go.drugbank.com/drugs/DB05659
    Investigational

    It is being developed jointly by Replidyne, Inc. and Forest Laboratories, Inc.